Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions

COVID-19

Interventions

BIOLOGICAL

GRAd-COV2

Single intramuscular administration.

Trial Locations (2)

Centro Ricerche Cliniche, Verona

INMI Spallanzani, Rome

All Listed Sponsors

collaborator

"Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani IRCCS"

NETWORK

lead

ReiThera Srl

INDUSTRY

NCT04528641 - Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine | Biotech Hunter | Biotech Hunter